Jaguar Health Regains Nasdaq Bid Price Compliance, Avoids Immediate Delisting
JAGX sits 17% above its 52-week low of $2.53.
Summary
Jaguar Health announced it has formally regained compliance with Nasdaq's minimum bid price rule, removing an immediate delisting threat, though it remains under a one-year monitoring period.
Key Events · Corporate Governance and Compliance · JAGX
-
Regained Nasdaq Bid Price Compliance
Jaguar Health, Inc. received formal notification from Nasdaq that it has regained compliance with Listing Rule 5550(a)(2), the Bid Price Rule, as of May 26, 2026.
-
Subject to Mandatory Panel Monitor
The Nasdaq Hearings Panel will maintain jurisdiction until September 1, 2026, and the company is subject to a mandatory one-year monitoring period until May 26, 2027. During this period, Jaguar Health will not receive a 180-day grace period if its bid price falls below $1.00 again, facing an immediate delist determination.
-
Follows Recent Financial Turnaround
This compliance news comes shortly after the company reported a significant Q1 2026 financial turnaround, including an 816% increase in net revenue and positive operating cash flow, which the CEO cited as a factor in regaining compliance.
Analysis · JAGX · Life Sciences
This filing is critical as Jaguar Health has formally regained compliance with Nasdaq's minimum bid price rule, removing the immediate threat of delisting that has loomed over the company for months. While the company will remain under a mandatory one-year monitoring period, during which it will not receive a grace period if the bid price falls below $1.00 again, the current compliance provides a crucial reprieve. This positive development follows a significant Q1 2026 financial turnaround, which the CEO highlighted as contributing to the improved position.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 43.9% of the 999 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $2.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2M. The 52-week trading range was $2.53 to $171.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.